Stem cell therapy Market By Cell Source, By Application, By Type : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global stem cell therapy market was valued at $205.12 million in 2021, and is projected to reach $928.64 million by 2031, registering a CAGR of 16.2% from 2022 to 2031.

The stem cell therapy is a promising strategy for regeneration of damaged organs, tissues or functions through the transplantation of stem cells. The cell therapy involves the direct administration of cells into the body for healing purposes. The units of therapy in this approach are single cells. It has been established as a useful therapy for hematologic malignancies and some solid tumors. However, some of the patients still die in allogeneic stem cell transplantation because T-lymphocytes cause fatal GVHD, and many are not cured in autologous stem cell transplantation as the disease recurs post-stem cell transplantation. Hematopoietic stem cell therapies provide methods for inducing lifelong tolerance to xenografts or allow novel treatment of autoimmune diseases, whereas the research and use of nonhematopoietic stem cells help minimize the toxicities of cancer therapy or cure non-malignant disorders.

The global stem cell therapy market is anticipated to show significant market growth during the forecast period, owing to increase in demand for stem cell therapy, increase in government support for R&D activities and increase in healthcare expenditure. Furthermore, increase in prevalence of diseases such as cancer, and new product launches associated with stem cell therapy are considerably contributing toward the market growth. However, limitations on use of embryonic stem cells due to ethical concerns and high cost of stem cell therapy are negatively impacting the market growth. Conversely, surge in the applications of induced pluripotent stem cells in embryonic stem cell therapy offers the lucrative opportunities for the growth of the market.

The global stem cell therapy market is segmented on the basis of cell source, application, type and region. Based on cell source, the market is classified into adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, cord blood/embryonic stem cells, other. Based on application, the market is classified into cancer, musculoskeletal disorders, wounds and injuries, cardiovascular diseases, gastrointestinal diseases, other. Based on type, the market is classified into allogeneic transplants and autologous transplants. Furthermore, the allogeneic transplants segment is sub-classified as pediatric and adult. Also, the autologous transplants segment is sub-classified as pediatric and adult. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

The major companies profiled in the report include: Allele Biotechnology and Pharmaceuticals, Inc., Astellas Pharma Inc, Fujifilm Holding Corporation (FUJIFILM Cellular Dynamics, Inc.), Mesoblast Ltd, Novadip Biosciences, NuVasive, Inc., Orthofix Holdings, Inc., Smith & Nephew plc, Takeda Pharmaceutical, and U.S. Stem Cell, Inc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the stem cell therapy market analysis from 2021 to 2031 to identify the prevailing stem cell therapy market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the stem cell therapy market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global stem cell therapy market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Cell Source

Adipose Tissue-Derived Mesenchymal Stem Cells
Bone Marrow-Derived Mesenchymal Stem Cells
Cord Blood/Embryonic Stem Cells
Other

By Application

Cancer
Musculoskeletal Disorder
Wounds and Injuries
Cardiovascular Disease
Other

By Type

Allogeneic Transplants
- Age
- Pediatric
- Adult
Autologous Transplants
- Age
- Pediatric
- Adult

By Region

North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Rest Of Europe
Asia-Pacific
- Japan
- India
- South Korea
- Rest Of Asia-Pacific
LAMEA
- Brazil
- Rest Of LAMEA
Key Market Players
- Allele Biotechnology and Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Fujifilm Holding Corporation
- Mesoblast Ltd.
- Novadip Biosciences
- NuVasive, Inc.
- Orthofix Holdings, Inc.
- Smith & Nephew plc
- Takeda Pharmaceutical Company Ltd
- U.S. Stem Cell, Inc.

Product Code: A10952

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: STEM CELL THERAPY MARKET, BY CELL SOURCE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Adipose Tissue-Derived Mesenchymal Stem Cells
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Bone Marrow-Derived Mesenchymal Stem Cells
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Cord Blood/Embryonic Stem Cells
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
4.5 Other
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country

CHAPTER 5: STEM CELL THERAPY MARKET, BY APPLICATION

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Cancer
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Musculoskeletal Disorder
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Wounds and Injuries
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
5.5 Cardiovascular Disease
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
5.6 Other
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country

CHAPTER 6: STEM CELL THERAPY MARKET, BY TYPE

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Allogeneic Transplants
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.2.4 Allogeneic Transplants Stem cell therapy Market by Age
  - 6.2.4.1 Pediatric Market size and forecast, by region
  - 6.2.4.2 Adult Market size and forecast, by region
6.3 Autologous Transplants
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.3.4 Autologous Transplants Stem cell therapy Market by Age
  - 6.3.4.1 Pediatric Market size and forecast, by region
  - 6.3.4.2 Adult Market size and forecast, by region

CHAPTER 7: STEM CELL THERAPY MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Cell Source
- 7.2.3 North America Market size and forecast, by Application
- 7.2.4 North America Market size and forecast, by Type
  - 7.2.4.1 North America Allogeneic Transplants Stem cell therapy Market by Age
  - 7.2.4.2 North America Autologous Transplants Stem cell therapy Market by Age
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Cell Source
  - 7.2.5.1.2 Market size and forecast, by Application
  - 7.2.5.1.3 Market size and forecast, by Type
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Cell Source
  - 7.2.5.2.2 Market size and forecast, by Application
  - 7.2.5.2.3 Market size and forecast, by Type
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Cell Source
- 7.3.3 Europe Market size and forecast, by Application
- 7.3.4 Europe Market size and forecast, by Type
  - 7.3.4.1 Europe Allogeneic Transplants Stem cell therapy Market by Age
  - 7.3.4.2 Europe Autologous Transplants Stem cell therapy Market by Age
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Cell Source
  - 7.3.5.1.2 Market size and forecast, by Application
  - 7.3.5.1.3 Market size and forecast, by Type
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Cell Source
  - 7.3.5.2.2 Market size and forecast, by Application
  - 7.3.5.2.3 Market size and forecast, by Type
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Cell Source
  - 7.3.5.3.2 Market size and forecast, by Application
  - 7.3.5.3.3 Market size and forecast, by Type
  - 7.3.5.4 Rest of Europe
  - 7.3.5.4.1 Market size and forecast, by Cell Source
  - 7.3.5.4.2 Market size and forecast, by Application
  - 7.3.5.4.3 Market size and forecast, by Type
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Cell Source
- 7.4.3 Asia-Pacific Market size and forecast, by Application
- 7.4.4 Asia-Pacific Market size and forecast, by Type
  - 7.4.4.1 Asia-Pacific Allogeneic Transplants Stem cell therapy Market by Age
  - 7.4.4.2 Asia-Pacific Autologous Transplants Stem cell therapy Market by Age
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Cell Source
  - 7.4.5.1.2 Market size and forecast, by Application
  - 7.4.5.1.3 Market size and forecast, by Type
  - 7.4.5.2 India
  - 7.4.5.2.1 Market size and forecast, by Cell Source
  - 7.4.5.2.2 Market size and forecast, by Application
  - 7.4.5.2.3 Market size and forecast, by Type
  - 7.4.5.3 South Korea
  - 7.4.5.3.1 Market size and forecast, by Cell Source
  - 7.4.5.3.2 Market size and forecast, by Application
  - 7.4.5.3.3 Market size and forecast, by Type
  - 7.4.5.4 Rest of Asia-Pacific
  - 7.4.5.4.1 Market size and forecast, by Cell Source
  - 7.4.5.4.2 Market size and forecast, by Application
  - 7.4.5.4.3 Market size and forecast, by Type
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Cell Source
- 7.5.3 LAMEA Market size and forecast, by Application
- 7.5.4 LAMEA Market size and forecast, by Type
  - 7.5.4.1 LAMEA Allogeneic Transplants Stem cell therapy Market by Age
  - 7.5.4.2 LAMEA Autologous Transplants Stem cell therapy Market by Age
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Cell Source
  - 7.5.5.1.2 Market size and forecast, by Application
  - 7.5.5.1.3 Market size and forecast, by Type
  - 7.5.5.2 Rest of LAMEA
  - 7.5.5.2.1 Market size and forecast, by Cell Source
  - 7.5.5.2.2 Market size and forecast, by Application
  - 7.5.5.2.3 Market size and forecast, by Type

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Allele Biotechnology and Pharmaceuticals, Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Astellas Pharma Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Fujifilm Holding Corporation
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Mesoblast Ltd.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Novadip Biosciences
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 NuVasive, Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Orthofix Holdings, Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Smith & Nephew plc
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Takeda Pharmaceutical Company Ltd
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 U.S. Stem Cell, Inc.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments